Code Pharma is a global pharmaceutical company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Antiviral drug Codivir
Code Pharma is the developer of the promising antiviral drug Codivir against COVID-19. Codivir is a short synthetic 16 amino-acid peptide, derived from the HIV-1 integrase, originally discovered at the Hebrew University in Israel.
Code Pharma's team discovered that the peptide had a direct antiviral effect against SARS-CoV-2, the coronavirus causing COVID-19.In-vitro studies conducted at the British research laboratory Virology Research Services then demonstrated a potent antiviral activity against SARS-CoV-2 and other RNA viruses.
Codivir is a short synthetic peptide derived from HIV virus that was found in preclinical and clinical examinations to either:
1. Leads to antiviral effect against RNA viruses.
2. Promote HIV-infected cells into self-induced death (apoptosis), and Lentivirus manipulation in the case of cancer therapy.